Media headlines about Agios Pharmaceuticals (NASDAQ:AGIO) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Agios Pharmaceuticals earned a daily sentiment score of 0.03 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 46.0825498349616 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the news stories that may have effected Accern Sentiment Analysis’s analysis:
- Agios Pharma (AGIO) Prices 7.1M Share Common Offering at $67/Sh (streetinsider.com)
- Here’s Why Agios (AGIO) Stock is Up More Than 50% in a Year (zacks.com)
- Here's Why Agios (AGIO) Stock is Up More Than 50% in a Year (finance.yahoo.com)
- Agios sizes up funding needs (finance.yahoo.com)
- Agios Pharmaceuticals Inc (AGIO) Expected to Announce Quarterly Sales of $16.07 Million (americanbankingnews.com)
A number of equities research analysts recently commented on AGIO shares. Cann restated a “buy” rating on shares of Agios Pharmaceuticals in a report on Tuesday, December 5th. BidaskClub lowered shares of Agios Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, December 16th. Oppenheimer set a $83.00 price objective on shares of Agios Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, November 17th. SunTrust Banks set a $80.00 price objective on shares of Agios Pharmaceuticals and gave the stock a “buy” rating in a report on Sunday, November 19th. Finally, Credit Suisse Group raised their price objective on shares of Agios Pharmaceuticals from $61.00 to $66.00 and gave the stock an “outperform” rating in a report on Thursday, November 2nd. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $77.64.
Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.78) by $0.19. Agios Pharmaceuticals had a negative net margin of 506.39% and a negative return on equity of 69.64%. The firm had revenue of $11.35 million for the quarter, compared to analyst estimates of $10.85 million. During the same period in the previous year, the business earned ($1.63) EPS. The company’s revenue was up 26.4% compared to the same quarter last year. equities research analysts expect that Agios Pharmaceuticals will post -6.59 EPS for the current year.
In other Agios Pharmaceuticals news, CEO David P. Schenkein sold 6,000 shares of Agios Pharmaceuticals stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $63.85, for a total value of $383,100.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Scott Biller sold 2,146 shares of Agios Pharmaceuticals stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $62.69, for a total transaction of $134,532.74. The disclosure for this sale can be found here. Insiders sold a total of 80,130 shares of company stock worth $5,561,250 over the last quarter. Company insiders own 5.43% of the company’s stock.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.